Antiaging Atlanta

HGH Human Growth Hormone Abstracts

  1. Adolescents with partial human growth hormone HGH deficiency develop alterations of body composition after HGH discontinuation and require follow-up.
  2. Adults with partial human growth hormone HGH deficiency have an adverse body composition.
  3. Antipituitary antibodies in adults with apparently idiopathic HGH human growth hormone deficiency and in adults with autoimmune endocrine diseases.
  4. Baseline characteristics and response to 2 years of growth hormone HGH replacement of hypopituitary patients with HGH deficiency due to adult onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS\
  5. Body mass index determines evoked human growth hormone HGH responsiveness in normal healthy male subjects: diagnostic caveat for adult HGH deficiency.
  6. Cardiac dimension and function in patients with childhood onset human growth hormone HGH deficiency, before and after human growth hormone retreatment in adult age.
  7. Comparison of continuation or cessation of growth hormone HGH therapy on body composition and metabolic status in adolescents with severe HGH deficiency at completion of linear growth.
  8. Cortical bone density is normal in prepubertal children with human growth hormone HGH deficiency, but initially decreases during HGH replacement due to early bone remodeling.
  9. Decreased quality of life in adult patients with HGH human growth hormone deficiency compared with general populations using the new validated, self weighted questionnaire, questions on life satisfaction hypopituitarism module.
  10. Do all patients with childhood onset growth hormone deficiency HGHD and ectopic neurohypophysis have persistent HGHD in adulthood?
  11. Does a gender related effect of growth hormone HGH replacement exist on cardiovascular risk factors cardiac morphology and performance and atherosclerosis? Results of a two-year open prospective study in young adult men and women with severe GH deficiency.
  12. Effect of human growth hormone HGH and/or testosterone replacement on the prostate in HGH-deficient adult patients.
  13. Effect of human growth hormone HGH treatment on bone in postpubertal HGH-deficient patients: a 2-year randomized, controlled, dose-ranging study.
  14. Effect of recombinant human growth hormone HGH replacement on the hypothalamic pituitary-adrenal axis in adult HGH deficient patients.
  15. Effects of human growth hormone HGH on ghrelin, leptin, and adiponectin in HGH-deficient patients.
  16. Effects of human growth hormone HGH replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with HGH deficiency: a stable isotope study.
  17. Efficacy and tolerability of an individualized dosing regimen for adult human growth hormone replacement therapy in comparison with fixed body weight-based dosing.
  18. Endothelial function and coagulant factors in human growth hormone HGH treated hypopituitary adults receiving desmopressin.
  19. Evaluation of diagnostic accuracy of insulin like growth factor IGF I and IGF binding protein 3 in growth hormone deficient children and adults using ROC plot analysis.
  20. Exercise training benefits human growth hormone HGH-deficient adults in the absence or presence of HGH treatment.
  21. Five years of human growth hormone HGH replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength.
  22. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood.
  23. High risk of adrenal insufficiency in adults previously treated for idiopathic childhood onset human growth hormone HGH deficiency.
  24. Human Growth hormone HGH dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.
  25. Human growth hormone HGH replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult human growth hormone-deficient patients.
  26. Human Growth hormone HGH replacement therapy in adult-onset hgh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial.
  27. Human growth hormone increases vascular cell adhesion molecule 1 expression: in vivo and in vitro evidence.
  28. Impact of human growth hormone HGH treatment on cardiovascular risk factors in HGH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials.
  29. Induction of postprandial inflammatory response in adult onset human growth hormone HGH deficiency is related to plasma remnant-like particle-cholesterol concentration.
  30. Limited efficacy of human growth hormone HGH during transition of HGH deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial.
  31. Long term HGH human growth hormone therapy in adulthood results in significant linear growth in siblings with a PROP 1 gene mutation.
  32. Long term improvement of quality of life during human growth hormone HGH replacement therapy in adults with HGH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H).
  33. Low bone mass is an infrequent feature of the adult human growth hormone HGH deficiency syndrome in middle-age adults and the elderly.
  34. Metabolic effects of 20 kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20K-hGH.
  35. Quality of life in childhood onset HGH human growth hormone-deficient patients in the transition phase from childhood to adulthood.
  36. Rational use of the laboratory for childhood and adult HGH human growth hormone deficiency.
  37. Reduced longevity in untreated patients with isolated HGH human growth hormone deficiency.
  38. Seeking the optimal target range for insulin-like growth factor I during the treatment of adult human growth hormone HGH disorders.
  39. Short- and long-term effects of human growth hormone HGH replacement on protein metabolism in HGH-deficient adults.
  40. Short term effects of human growth hormone HGH treatment or deprivation on cardiovascular risk parameters and intima media thickness at carotid arteries in patients with severe HGH deficiency.
  41. The characteristics of quality of life impairment in adult growth hormone HGH deficient survivors of cancer and their response to HGH replacement therapy.
  42. The effect of cessation of human growth hormone HGH therapy on bone mineral accretion in HGH deficient adolescents at the completion of linear growth.
  43. The Impact of congenital, severe, untreated human growth hormone HGH deficiency on bone size and density in young adults: insights from genetic HGH-releasing hormone receptor deficiency.
  44. The mathematical model for total pubertal growth in idiopathic human growth hormone HGH deficiency suggests a moderate role of HGH dose.
  45. The usefulness of the combined human growth hormone HGH -releasing hormone and arginine stimulation test in the diagnosis of radiation-induced HGH deficiency is dependent on the post-irradiation time interval.
  46. Bone status and fracture prevalence in Russian adults with childhood-onset human growth hormone HGH deficiency.
  47. Clinical review: Human Growth hormone HGH and cardiovascular risk factors.
  48. Effect of human growth hormone HGH on glycerol and free fatty acid metabolism during exhaustive exercise in GH-deficient adults.
  49. Human growth hormone HGH replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.
  50. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without human growth hormone HGH replacement therapy.
  51. Common carotid intima-media thickness in human growth hormone HGH-deficient adolescents: a prospective study after HGH withdrawal and restarting HGH replacement.
  52. Diagnostic and therapeutic advances in human growth hormone HGH insensitivity.
  53. Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of human growth hormone HGH treatment on these parameters.
  54. Influence of body mass index and gender on human growth hormone HGH responses to HGH-releasing hormone plus arginine and insulin tolerance tests.
  55. Peripheral inflammatory and fibrinolytic markers in adolescents with human growth hormone deficiency HGH-D: relation to postprandial dyslipidemia.
  56. Treatment of cachexia with HGH releasing peptide ghrelin in patients with COPD.
  57. Human Growth hormone releasing peptide-2 (HGHRP-2), like ghrelin, increases food intake in healthy men.
  58. Peripheral inflammatory and fibrinolytic markers in adolescents with human growth hormone deficiency HGH-D: relation to postprandial dyslipidemia.
  59. Short-term administration of supraphysiological recombinant human growth hormone HGH does not increase maximum endurance exercise capacity in healthy, active young men and women with normal HGH-insulin-like growth factor I axes.
  60. Platelet hyperactivation in maintained human growth hormone HGH-deficient childhood patients after therapy withdrawal as a putative earlier marker of increased cardiovascular risk.
| Site Map | Links & Resources | Contact Us | ©2004 - 2005 Anti-Aging & Weight Loss Medicine, LLC - Disclaimer and Copyright